Concurrent chemoradiotherapy in patients with nasopharyngeal cancer: Prognostic significance of low expression of bax

Neoplasma

Volumn 53, Issue 5, 2006, Pages 450-456

  Kang, S Y ^a   Oh, Y T ^a   Han, J H ^a   Choi, J H ^a   Lim, H Y ^a   Kim, H I ^a   Lee, H W ^a   Jang, J H ^a   Park, J S ^a   Kim, H C ^a   Kang, S ^a   Chun, M ^a   Kim, C H ^a   Joo, H J ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Bax; Chemoradiotherapy; Low expression; Nasopharyngeal cancer; Prognosis

Indexed keywords

CISPLATIN; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOPENIA; MALE; NASOPHARYNX CANCER; ORAL MUCOSAL DISEASE; OTOTOXICITY; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DERMATITIS; TREATMENT RESPONSE; XEROSTOMIA;

EID: 33750627137     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. FANDI A, ALTUN M, AZIL N, ARMAND JP, CVITKOVIC E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 1994; 21: 382-397.
2. CHAN AT, TEO PM, HUANG DP. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 2004; 31: 794-801.
3. SHIN HR, AHN Y-O, BAE J-M, SHIN M-H, LEE D-H et al. Cancer Incidence in Korea. Cancer Res Treat 2002; 34: 405-408.
4. WONG JR. Is chemotherapy beneficial in the treatment of locoregionally advanced nasopharyngeal carcinoma? Cancer 1998; 83: 2255-2258.
5. COOPER JS, LEE H, TORREY M, HOCHSTER H. Improved outcome secondary to concurrent chemoradiotherapy for advanced carcinoma of the nasopharynx: preliminary corroboration of the intergroup experience. Int J Radiat Oncol Biol Phys 2000; 47: 861-866.
6. HUNCHAREK M, KUPELNICK B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 2002; 25: 219-223.
7. INTERNATIONAL NASOPHRYNX CANCER STUDY GROUP. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, MO) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 1996; 35: 463-469.
8. CHUA DT, SHAM JS, CHOY D, LORVIDHAYA V, SUMITSAWAN Y et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 1998; 83: 2270-2283.
9. HAREYAMA M, SAKATA K, SHIRATO H, NISHIOKA T, NISHIO M et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 2002; 94: 2217-2223.
10. CHI KH, CHANG YC, GUO WY, LEUNG MJ, SHIAU CY et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002; 52: 1238-1244.
11. Al-SARRAF M, LeBLANC M, GIRI PG, FU KK, COOPER J et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-1317.
12. LIN JC, JAN JS, HSU CY, LIANG WM, JIANG RS et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003; 21: 631-637.
13. CHUA DT, SHAM JS, AU GK, CHOY D. Concomitant chemo-irradiation for stage III-IV nasopharyngeal carcinoma in Chinese patients: results of a matched cohort analysis. Int J Radiat Oncol Biol Phys 2002; 53: 334-343.
14. CHAB AT, TEO PM, NGAN RK, LEUNG TW, LAU WH et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002; 20: 2038-2044.
15. AMERICAN JOINT COMMITTEE ON CACNER. AJCC cancer staging manual. 6th ed. New York: Springer 2002.
16. MILLER AB, HOOGSTRATEN B, STAQUET M, WINKLER A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
17. KAPLAN EL, MEIER P. Non-parametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457-481.
18. COX DR. Regression models and life tables. J R Statist Soc 1972; 34: 187-220.
19. TAN EH, CHUA ET, WEE J, TAN T, FONG KW et al. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: toxicities and preliminary results. Int J Radiat Oncol Biol Phys 1999; 45: 597-601.
20. CHENG SH, JIAN JJ, TSAI SY, YEN KL, CHU NM et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1323-1330.
21. TEO P, YU P, LEE WY, LEUNG SF, KWAN WH et al. Significant prognosticators after primary radiotherapy in 903 non-disseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys 1996; 36: 291-304.
22. FARIAS TP, DIAS FL, LIMA RA, KLIGERMAN J, de SA GM et al. Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2003; 129: 794-799.
23. REED JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17: 2941-2953.
24. KERR JF, WINTERFORD CM, HARMON BV. Apoptosis. its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-2026.
25. YIN C, KNUDSON CM, KORSMEYER SJ, Van DYKE T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637-640.
26. LING CC, GUO M, CHEN CH, DELOHEREY T. Radiation-induced apoptosis: effects of cell age and dose fractionation. Cancer Res 1995; 55: 5207-5212.
27. MASUDA M, SHINOKUMA A, HIRAKAWA N, NAKASHIMA T, KOMIYAMA S. Expression of bcl-2-, p53, and K.i-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment. Head Neck 1998; 20: 640-644.
28. TSAI ST, JIN YT, LEUNG HW, WANG ST, TSAO CJ et al. Bcl-2 and proliferating cell nuclear antigen (PCNA) expression correlates with subsequent local recurrence in nasopharyngeal carcinomas. Anticancer Res 1998; 18: 2849-2854.
29. GENC E, HOSAL AS, GEDIKOGLU G, OZYAR E, SOZERI B. Prognostic value of p53, proliferating cell nuclear antigen, and Ki-67 expression in undifferentiated nasopharyngeal carcinomas. Otolaryngol Head Neck Surg 2000; 122: 868-873.
30. JAYASURYA A, DHEEN ST, YAP WM, TAN NG, NG YK et al. Inducible nitric oxide synthase and bcl-2 expression in nasopharyngeal cancer: correlation with outcome of patients after radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56: 837-845.
31. MA BB, POON TC, TO KF, ZEE B, MO FK et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma- a prospective study. Head Neck 2003; 25: 864-872.
32. BAEKELANDT M, HOLM R, NESLAND JM, TROPE CG, KRISTENSEN GB. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol 2000; 18: 3775-3781.
33. KUPRYJANCZYK J, SZYMANSKA T, MADRY R, TIMOREK A, STELMACHOW J et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 2003; 88: 848-854.
34. XIE X, CLAUSEN OP, De ANGELIS P, BOYSEN M. Bax expression has prognostic significance that is enhanced when combined with AgNOR counts in glottic carcinomas. Br J Cancer 1998; 78: 100-105.
35. XIE X, CLAUSEN OP, De ANGELIS P, BOYSEN M. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999; 86: 913-920.
36. ITO T, FUJIEDA S, TSUZUKI H, FAN G, SUGIMOTO C et al. Decreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma. Cancer Lett 1999; 140: 81-91.
37. BANDOH N, HAYASHI T, KISHIBE K, TAKAHARA M, IMADA M et al. Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma. Cancer 2002; 94: 1968-1980.
38. POLLACK A, COWDEN D, TRONCOSO P, ZAGARS GK, von ESCHENBACH AC et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 2003; 97: 1630-1638.
39. POSNER MR, COLEVAS AD, TISHLER RB. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol 2000; 27(4) Suppl 8: 13-24.
40. SHIN DM, GLISSON BS, KHURI FR, LIPPMAN SM, GINSBERG L et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002; 95: 322-330.
41. GLISSON BS, MURPHY BA, FRENETTE G, KHURI FR, FORASTIERE AA. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002; 20: 1593-1599.